- Conditions
- Congenital Hyperinsulinism
- Interventions
- HM15136
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 4:16 AM EDT